baber/WOPTO huggingface dataset:
Patent AU-1767392-A (AU)
Title: Use of 1-(beta -d-arabinofuranosyl)-5-propynyluracil for lowering serum cholesterol
IPC: A61K31/7052
Filed: 1992-05-29
Abstract: PCT No. PCT/GB92/00971 Sec. 371 Date Feb. 11, 1993 Sec. 102(e) Date Feb. 11, 1993 PCT Filed May 29, 1992 PCT Pub. No. WO92/21352 PCT Pub. Date Dec. 10, 1992.The use of 1-( beta -D-arabinofuranosyl)-5-propynyluracil or a pharmaceutically acceptable salt or physiologically labile ester thereof for lowering serum cholesterol, particularly low density lipoprotein cholesterol levels in a human subject.
Patent AU-1769597-A (AU)
Title: Morphine and diamorphine salts of anionic non-narcotic analgesics of the type substituted carboxylic acid, processes for their production, their use, and pharmaceutical preparations comprising these salts
Inventor: ASMUSSEN BODO
IPC: C07D489/04
Filed: 1997-02-15
Abstract: PCT No. PCT/EP97/00711 Sec. 371 Date Oct. 28, 1999 Sec. 102(e) Date Oct. 28, 1999 PCT Filed Feb. 15, 1997 PCT Pub. No. WO97/31918 PCT Pub. Date Sep. 4, 1997The present invention relates to morphine and diamorphine salts of anionic non-narcotic analgesics belonging to the type of substituted carboxylic acids, preferably the morphine and diamorphine salts of diclofenac (Formula 1); to processes for their production, the use of these salts in the treatment of diseases, as well as to pharmaceutical preparations comprising these salts.
Patent AU-1987783-A (AU)
Title: Ethylene-propylene copolymer sutures
Inventor: MENEZES EDGAR VITHAL
IPC: C08L23/14
Filed: 1983-10-04
Abstract: Sterile surgical monofilament sutures are disclosed. The sutures are made from ethylene-propylene copolymers, and have improved compliance, compared with polypropylene homopolymer sutures.
Patent AU-2234599-A (AU)
Title: Correction tape having dye migration blocking properties
Inventor: NIENABER RENATE
IPC: B32B7/023
Filed: 1999-01-15
Abstract: The present invention is directed to a correction tape that has a support member, a transfer layer, and a correction medium layer. The correction medium layer includes an opacifying pigment, binding polymer, and bleed inhibitor. Suitable bleed inhibitors include polyvinyl amines, phospholipids, tallow amines or combinations thereof. The bleed inhibitor is present in an amount of between about 0.1 % to 10 % by weight.
Patent AU-2290895-A (AU)
Title: Simulcast of interactive signals with a conventional video signal
Inventor: HARPER GREGORY W
IPC: H04N7/173
Filed: 1995-04-14
Abstract: A system for simulcasting a fully interactive program with a normal conventional program in the same standard video signal bandwidth. It allows active participation by subscribers who have interactive components (600) connected to a television (186) or personal computer display (187), as well as normal viewing of the conventional program by viewers with conventional television sets (186). An important feature is that interactivity is offered as an option, without any degradation or interruption in program content to users who do not have the interactive components (600). Interactivity is personalized through the use of alternative audio responses and/or graphic displays that can be provided as part of the transmitted video signal bandwidth. The interactive elements are presented to the subscriber either immediately after subscriber entry and/or later at transparent "trigger points" (900). At trigger points (900), program content is subtly altered to present specialized attention to each interactive subscriber.
Patent AU-2437292-A (AU)
Title: Streptolysin o derivatives
IPC: C12N1/15
Filed: 1992-07-31
Abstract: Disclosed herein are derivatives of Streptolysin 0 produced by recombinant DNA techniques. In an embodiment, the derivative is soluble upon expression and has a specific hemolytic activity of about 3.6x104 hemolytic units per milligram.
Patent AU-2549095-A (AU)
Title: Hepatocyte-selective oil-in-water emulsion
Inventor: COUNSELL RAYMOND E
IPC: A61K51/12
Filed: 1995-05-16
Abstract: PCT No. PCT/US95/05974 Sec. 371 Date Nov. 15, 1996 Sec. 102(e) Date Nov. 15, 1996 PCT Filed May 16, 1995 PCT Pub. No. WO95/31181 PCT Pub. Date Nov. 23, 1995A heat and shelf-stable oil-in-water emulsion useful as a tissue or cell-selective delivery vehicle. Radioactive or stable, synthetic or semi-synthetic polyhalogenated triglycerides, such as 2-oleoylglycerol-1,3-bis[7-(3-amino-2,4,6-triiodophenyl)heptanoate] or 2-oleoylglycerol-1,3-bis[ omega -(3,5-bis-trifluoromethyl)-heptanoate] or phenyl acetate, can be incorporated into the lipophilic core of a lipoprotein-like emulsion particle. The lipophilic core is surrounded by a phospholipid membrane comprising cholesterol and apolipoproteins. For hepatocyte-selective delivery, the emulsion is chylomicron remnant-like by being in a size range of 50 to 200 nm as measured by number weighting analysis with a narrow size distribution (<2% greater than 300 nm) and having a composition simulating naturally-occurring chylomicron remnants. Use of cholesterol in the emulsion formula facilitates association of apolipoproteins, especially Apo E which are recognized by liver cells and necessary for binding and uptake. Stability and size constraints can be achieved by ultra high energy mixing equipment, such as the MicroFluidizer (Microfluidics Corp., Newton, Mass.) to form the emulsion. In preferred embodiments, osmolality of the emulsion is controlled by glycerol rather than normal saline.
Patent AU-2573800-A (AU)
Title: Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism
Inventor: IGA KATSUMI
IPC: A61K47/16
Filed: 2000-02-18
Abstract: The present invention provides a percutaneous absorption preparation which comprises a compound having angiotensin II antagonistic activity and which allows the compound to permeate through the skin at a desirable rate for a prolonged period.
Patent AU-2633388-A (AU)
Title: Method for the treatment of non-specific inflammation
Inventor: ANDERSON DONALD CARROLL
IPC: A61P31/04
Filed: 1988-11-29
Abstract: The invention provides a method for treating inflammation caused by the non-specific defense system of a mammalian subject. Inflammation is treated by providing the subject with an anti-inflammatory agent capable of inhibiting granulocyte-endothelial cell adhesion.
Patent AU-2655595-A (AU)
Title: A catheter system and method for providing cardiopulmonary bypass pump support during heart surgery
Inventor: SWEEZER WILLIAM P
IPC: A61M60/117
Filed: 1995-05-26
Abstract: A catheter system and devices for achieving total cardiopulmonary bypass during heart surgery are provided. The venous perfusion catheter has first and second balloons occluding the inferior and superior vena cava thereby precluding blood flow into the right atrium. An arterial perfusion catheter is inserted, advanced and positioned in the ascending aorta cephalid of the junction of the coronary arteries with the aortic root. A second flexible arterial cannula is mounted in sliding relationship with the first flexible cannula and carries an inflatable balloon adjacent its distal end to provide for occlusion of the ascending aorta. A first flexible cannula has a first lumen and an arterial venting orifice communicating with the first lumen defining a single flow path for the passage of cardioplegia solution to arrest the heart or for the evacuation of blood from the aortic root. A third lumen extends axially through the first flexible arterial cannula and communicates with a multiplicity of openings in the distal tip for suctioning blood from the left ventricle. The second flexible cannula of the arterial perfusion catheter has a first cavity extending axially therethrough that communicates with an opening at its distal tip to permit the passage of blood delivered by the cardiopulmonary bypass pump into arterial circulation. Both the venous and arterial perfusion catheters have a plurality of radially and oppositely spaced steering lumens and a plurality of steering cables fixed to the distal ends to achieve omnidirectional articulation. <IMAGE>
Patent AU-2866297-A (AU)
Title: Neuraminic acid derivatives, their preparation and their medical use
Inventor: HONDA TAKESHI
IPC: A61P31/16
Filed: 1997-07-16
Abstract: Compounds of formula (I): <CHEM> Äin which R<1> is alkyl or haloalkyl; R<2> and R<3> each represents hydrogen or aliphatic acyl; X is hydroxy, halogen, alkoxy, or a group of formula R<a>O-, where R<a> is aliphatic acyl; Y is a group of formula R<b>R<c>N- or R<b>R<c>N-O-, where R<b> and R<c> each is hydrogen or alkyl; and Z is oxygen or sulphurÜ have excellent sialidase inhibitory activity and are therefore useful for the treatment and prevention of influenza and other viral diseases where the replication of the virus is susceptible to sialidase inhibitors.
Patent AU-2924584-A (AU)
Title: Mass spectrometer pyrolysis inlet system
Inventor: OTTLEY THOMAS WILLIAM
IPC: H01J49/04
Filed: 1984-06-08
Abstract: The invention relates to an inlet system for use in a mass spectrometer which comprises a capillary tube 10 for introducing ions for analysis into the ion source of the spectrometer. An expansion chamber 14 arranged at the end of the capillary tube 10 has an aperture sealingly connectable to a tube 16 containing a sample to be analysed. A piston 18 disposed within the expansion chamber 14 acts as a closure member for opening and closing the said aperture. A pumping line 25 is provided for evacuating the expansion chamber 14 to low vacuum after communication is established between the expansion chamber and the sample tube 16 and the piston 18 seals off the pumping line from the expansion chamber 14 after a low vacuum has been achieved in the latter chamber to permit evacuation of the expansion chamber 14 to a higher vacuum by way of the capillary tube 10 by a diffusion pump evacuating the space within the mass spectrometer.
Patent AU-3111195-A (AU)
Title: Alginate fibres, manufacture and use
Inventor: MAHONEY PETER M J
IPC: A61K9/70
Filed: 1995-07-14
Abstract: PCT No. PCT/EP95/02772 Sec. 371 Date Jul. 7, 1997 Sec. 102(e) Date Jul. 7, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02285 PCT Pub. Date Feb. 1, 1996A non-immunogenic, bioerodible implantation composition which comprises alginate fibres.
Patent AU-3156401-A (AU)
Title: Powder mixture or composite powder, a method for production thereof and the use thereof in composite materials
Inventor: MENDE BERND
IPC: B22F9/24
Filed: 2000-12-11
Abstract: A process is described for the preparation of powder mixtures or composite powders from at least one first type of powder from the group consisting of high-melting metals, hard materials and ceramic powders and at least one second type of powder from the group consisting of binder metals, binder-metal mixed crystals and binder-metal alloys, where the second type of powder is formed from precursor compounds in the form of water-soluble salts in an aqueous suspension of the first type of powder by precipitation as oxalate, removal of the mother liquor and reduction to the metal.
Patent AU-3251989-A (AU)
Title: Process for preparing taxol
Inventor: DENIS JEAN-NOEL
IPC: C07D305/14
Filed: 1989-04-06
Abstract: Process for preparing taxol by the condensation of a (2R, 3S) acid of general formula (I) with a taxan derivative of general formula (II), followed by the removal of the groups R2 and R3 protecting the hydroxy groups.   <IMAGE> (II)  <IMAGE> (I)
Patent AU-3302100-A (AU)
Title: Mixed articles comprising a rigid part and a part based on thermoplastic material
Inventor: CHOMIER DIDIER
IPC: B29L22/00
Filed: 2000-03-21
Abstract: The invention concerns the production of articles comprising at least a rigid element (1) and at least an element (2) made of a thermoplastic material obtained by moulding. The rigid element (1) has a profiled transverse section defining a concave space, wherein is positioned at least partly an element made of thermoplastic material.
Patent AU-3328793-A (AU)
Title: Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
Inventor: HOSTETLER KARL Y
IPC: A61K47/48
Filed: 1992-12-17
Abstract: Compounds are disclosed for treating viral infections due to herpes, influenza, hepatitis B, Epstein-Barr, and varicella zoster viruses, as well as cytomegalovirus and human immunodeficiency virus (HIV) by means of lipid derivatives of antiviral agents. The compounds consist of lipid derivatives of phosphonoacids having antiviral activity which are linked, commonly through the phosphate group of the phosphonoacid, to one of a selected group of lipids. The lipophilic nature of these compounds provides advantages over the use of the phosphonoacids alone. It also makes it possible to incorporate them into the lamellar structure of liposomes when combined with similar molecules. In the form of liposomes, these antiviral molecules are preferentially taken up by macrophages and monocytes, cells which have been found to harbor the target human immunodeficiency virus (HIV). Additional site specificity may be incorporated into the liposomes with the addition of ligands, such as monoclonal antibodies or other peptides or proteins which bind to viral proteins. Effective phosphonoacids are phosphonoformic acid or phosphonoacetic acid; lipid groups may be glycolipids, sphingolipids, phospholipids, glycerolipids, or fatty acids. The compounds persist, after intracellular hydrolysis, as the antiviral phosphonoacids. The compounds are effective in improving the efficacy of antiviral phosphonoacids by prolonging the antiviral activity after the administration of the drug has ended, and in preventing retroviral replication in HIV infections which have become resistant to therapy with conventional forms of the antiretroviral agents.
Patent AU-3390089-A (AU)
Title: Ultrasonic contrast medium made up of small gas bubbles and fatty-acid-containing microparticles
Inventor: LANGE LOTHER PROF
IPC: A61B8/00
Filed: 1989-05-01
Abstract: Contrast agents for ultrasonic diagnosis consisting of gas bubbles and microparticles are described and are characterised in that they contain as microparticles a mixture of at least one (C10-C20)-fatty acid with at least one solid which has no interfacial activity, suspended in a liquid vehicle. They provide contrast in ultrasonic imaging of the right and left heart, the myocardium and other organs such as the liver, spleen and kidney, after intravenous administration.
Patent AU-3474384-A (AU)
Title: Forming reinforced thermoplastics
Inventor: CATTANACH JAMES BUCHAN
IPC: B29C43/10
Filed: 1984-10-26
Abstract: A method of improving the surface finish of a fibre-reinforced thermoplastic article in which the fibres are present as superimposed layers of continuous, aligned fibres comprising pressing the layers at a temperature above the softening point of the thermoplastic of the article characterised in that the pressure is transmitted to the superimposed layers through a resilient member and that a metal foil having a thickness of between 0.05 and 0.5 mm, preferably between 0.075 and 0.25 mm, is present between the resilient member and the reinforced article to be pressed.
Patent AU-3786085-A (AU)
Title: Photochromic substances
Inventor: MANFRED MELZIG
IPC: G03C1/72
Filed: 1984-12-17
Abstract: New spiro-(indolino-2,3'(3H) -naphth(2,1-6)(1,4)oxazine cpds. of formula (I) R1, R2 and R3 = H, -CN, -SCN, -NO2, -X, -CH2X, -CX3, -OR, -SR, -COR, -COOR or =Ar; X = halogen; =Ar= annelated (hetero)aromatic ring system; R4, R5, R6 and R7 = H, -R, -CH2R, -NH2, -NHR, -N(R)2, -OR or -SR but at least one of R4, R5 and R6 not = Me if R7 = H; R = H, 1-8C alkyl or (hetero)aryl. R7 = -CH3, -C2H5, -C6H11, -NC5H10 or -N(C6H11)2.
Patent AU-3989793-A (AU)
Title: Acyl lactylates as antimicrobial actives
Inventor: CARTER PETER
IPC: A61K8/00
Filed: 1993-05-28
Abstract: The use of an acyl lactylate of the following structure (I) <CHEM> where RCO represents a C4-C7 acyl radical: M represents H or a counter ion chosen from alkaline metal, alkaline earth metal, zinc, silver, ammonium or substituted ammonium having one or more C1-C3 alkyl or hydroxy alkyl group(s); a is an integer of from 1 to 3; b is 1 or 2; or mixtures of such acyl lactylates; to inhibit or prevent the growth of microorganisms or to reduce the amount of microorganisms present.
Patent AU-4061502-A (AU)
Title: Gutter and flushing system for milking parlors
Inventor: EPPERS PAUL A
IPC: A01K1/12
Filed: 2002-05-13
Abstract: A milking parlor has a flushing channel along a zigzag rump rail (124) for flushing cow manure therealong. The rump rail (124) is a continuous tubular conduit having upper portions thereof (146) cut-out (148) at end segments (134) to provide open-top gutter channels (138) receiving manure therein and interdigitated with closed-top flow channels (140) in side segments (128) conducting and passing the manure.
Patent AU-4114597-A (AU)
Title: Self-tapping screw, in particular concrete screw
Inventor: GERHARD ANTON
IPC: F16B25/02
Filed: 1997-07-18
Abstract: PCT No. PCT/EP97/03867 Sec. 371 Date Jan. 25, 1999 Sec. 102(e) Date Jan. 25, 1999 PCT Filed Jul. 18, 1997 PCT Pub. No. WO98/04842 PCT Pub. Date Feb. 5, 1998A self-tapping screw, in particular a concrete screw, comprises a cylindrical core with a central longitudinal axis and a thread designed in a single piece with the core and provided, in the area of its periphery, with cutting notches formed by triangles open towards the periphery of the thread. The flanks of the thread extend substantially in parallel to each other radially to the central longitudinal axis.
Patent AU-4196789-A (AU)
Title: Biological diagnostic assay system
Inventor: LINDHOLM EDWARD P
IPC: G01N33/543
Filed: 1989-07-31
Abstract: A multilayer diagnostic assay element wherein glyoxyl agarose, an aldehyde group - derivatized agarose, is utilized in one or more layers of the element. In a preferred embodiment the glyoxyl agarose is ued to immobilize biological species such as a protein in a layer of the element.
Patent AU-4296300-A (AU)
Title: Crystallising polyether polyols, a method for producing them and use of the same
Inventor: SCHAFER WALTER
IPC: C08G18/48
Filed: 2000-04-18
Abstract: This invention relates to crystallizing polyether polyols which can be produced firstly by the reaction of propylene oxide and polyhydroxy compounds in the presence of an alkoxy compound which contains zinc and/or aluminium atoms to form a crystallizing polyether polyol with an average molecular weight Mn from 500 to 5000, followed by the further reaction of the crystallizing polyether polyol which is thus obtained with 10 to 90% by weight, with respect to the amount of crystallizing polyol, of an epoxide in the presence of a catalyst which does not polymerize propylene oxide stereospecifically, to form a crystallizing polyether polyol with an average molecular weight Mn from 1000 to 20,000. The invention further relates to a method for the production thereof and to the use thereof for the production of polyurethane materials, particularly polyurethane foams, polyurethane elastomers and polyurethane coatings.
Patent AU-4304596-A (AU)
Title: A process for the preparation of substituted 4-ethyl-piperidines and an intermediate for the preparation of same
Inventor: PETERS DAN
IPC: C07D453/02
Filed: 1995-12-15
Abstract: PCT No. PCT/EP95/04975 Sec. 371 Date Sep. 4, 1997 Sec. 102(e) Date Sep. 4, 1997 PCT Filed Dec. 15, 1995 PCT Pub. No. WO96/19452 PCT Pub. Date Jun. 27, 1996   <IMAGE>  (I)  Compounds of structure (I) in which R is C1-8alkyl(phenyl)p, C2-8alkenyl(phenyl)p, C2-8 alkenyl(phenyl)p, C3-8cycloalkyl or C1-8alkylC3-8cycloalkyl; p is 0 to 2; n is 0 to 6; A is a bond, oxygen, sulphur or NR1; R1 is hydrogen, C1-8alkylphenylC1-4alkyl; m is 0 to 3; and Ar is aryl or heteroaryl, each of which may be optionally substituted, and salts thereof processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy, in particular as calcium blocking agents.
Patent AU-4340096-A (AU)
Title: A night depository or safe deposit apparatus, a control unit and an interface card for the same
Inventor: KELLER STEEN
IPC: E05G7/00
Filed: 1996-01-12
Abstract: A night depository or safe deposit apparatus for receiving and holding a deposit of money or other valuables comprises a fire- and burglarproof housing defining an internal storage space and having an entrance opening. Besides, the depository comprises inlet means bridging the entrance opening and the internal storage space and permitting the transfer of a deposit from the outside into the internal storage space, code generating means accessible from the outside and serving to generate a code signal by actuating the code generating means, and control means connected to the code generating means and to the inlet means and adapted to perform a verification of a code signal generated by the code generating means prior to actuation of the inlet means for performing a deposit. The control means comprise PC means adapted to perform said verification of the code signal by comparison of the code signal with a code input to the PC means, and the PC means is adapted to communicate with external data processing means for input of control data from the external data processing means, including verified codes, giving access to perform deposits in the internal storage space in the housing of the night depository or safe deposit apparatus, and for output of data for the external data processing means, including data representing the operation and function of the night depository or safe deposit apparatus. In this manner, a night depository or safe deposit apparatus is obtained which may be integrated in an existing data system and be programmed on-line and transmit information on-line, including data regarding the function of the night depository or safe deposit apparatus.
Patent AU-4458885-A (AU)
Title: Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers
Inventor: ANDERSON PORTER W
IPC: A61K39/09
Filed: 1985-07-04
Abstract: The invention relates to immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers, methods for the preparation of the conjugates, a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in humans. Also disclosed are methods for including active immunization against systemic infection in young mammals caused by bacterial pathogens comprising the administration of an immunogenic amount of the above-described conjugate.
Patent AU-4650697-A (AU)
Title: Methods and compositions for preventing and treating heartburn
Inventor: KORN SCOTT H
IPC: A61K31/426
Filed: 1997-09-30
Abstract: A method for preventing heartburn episodes in a patient at risk to development of heartburn, comprising administering to the patient, following the heartburn inducing event but prior to development of heartburn, a composition comprising a pharmaceutically effective amount of an H2 antagonist and an amount of antacid having between about 15 mEq and 46 mEq acid neutralizing capacity.
Patent AU-4699897-A (AU)
Title: Novel (-)-enantiomers of (cis)-3,4-chroman derivatives useful in the preve ntion or treatment of estrogen related diseases or syndromes
Inventor: JACOBSEN PAUL
IPC: A61K31/353
Filed: 1997-10-28
Abstract: The present invention relates to therapeutically active compounds of formula (I), a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
Patent AU-4774897-A (AU)
Title: Glycoconjugates of modified camptothecin derivatives (a- or b-ring linkage)
Inventor: LERCHEN HANS-GEORG
IPC: C07K5/068
Filed: 1997-09-17
Abstract: PCT No. PCT/EP97/05089 Sec. 371 Date Mar. 24, 1999 Sec. 102(e) Date Mar. 24, 1999 PCT Filed Sep. 17, 1997 PCT Pub. No. WO98/14468 PCT Pub. Date Apr. 9, 1998The present invention relates to glycoconjugates of camptothecin derivatives in which at least one carbohydrate component is linked via suitable spacers with the A or B ring of a camptothecin derivative. The invention furthermore relates to processes for preparing the compounds according to the invention and to their use as medicaments, in particular in connection with cancer.